Flatley Jay T. - 19 Oct 2022 Form 4 Insider Report for Zymergen Inc.

Reporting relationship: Chairman and Acting CEO, Director
Issuer ticker: N/A
Reported as of: 19 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2022, 20:17:59 UTC
Prior SEC filing: 01 Jul 2022
Next SEC filing: 05 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Celeste Ferber, attorney-in-fact

Key filing fact

Flatley Jay T. filed Form 4 for Zymergen Inc. on 19 Oct 2022.

Key facts

This page summarizes Flatley Jay T.'s Form 4 filing for Zymergen Inc..
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 19 Oct 2022, 20:17.

Change

Previous filing in this sequence was filed on 01 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZY transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -144,789
Change %: -100%
Price
Shares after: 0
Date: 19 Oct 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZY transaction Derivative

Stock Options

Disposed to Issuer

Transaction value: $0
Shares: -1,520,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,520,000
Exercise price: $12.33
Footnotes: F2

ZY transaction Derivative

Stock Options

Disposed to Issuer

Transaction value: $0
Shares: -189,125
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 189,125
Exercise price: $8.52
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Flatley Jay T. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of July 24, 2022 (the "Merger Agreement"), by and among Ginkgo Bioworks Holdings, Inc. ("Ginkgo"), Pepper Merger Subsidiary Inc. and the Issuer, each share of the Issuer's common stock was cancelled and converted into a right to receive 0.9179 of a share of Class A common stock of Ginkgo (the "Merger Consideration"), together with cash in lieu of any fractional shares of Class A common stock of Ginkgo.

Footnote F2

Immediately prior to the effective time of the merger (the "Effective Time"), all outstanding Issuer stock options vested in full pursuant to the terms of the agreements governing such stock options. Pursuant to the Merger Agreement, at the Effective Time, each Issuer stock option with an exercise price per share equal to or greater than the Merger Consideration Value (as defined in the Merger Agreement) was cancelled for no consideration.